Rheumatoid arthritis affects approximately 1.6 million people in the United States and as much as 1% of the population worldwide. Up to 90% of the time RA patients who fail methotrexate are prescribed anti-TNF therapies as a first line b/tsDMARD, the world’s largest selling drug class, but most do not respond to treatment.‍

Ulcerative Colitis is the most common inflammatory bowel disease worldwide, affecting roughly 1 million people in the United States alone. Accounting for 250K+ provider visits and nearly $4B in medical costs, the disease is a lifelong disorder with a significant impact on both physical and mental health and clinical response to targeted therapies are as low as only 20%-50%.

Psoriatic arthritis is a chronic inflammatory arthritis associated with psoriasis and affects about 1% of the global populations. Similar in treatment path to rheumatoid arthritis, most patients with PsA who reach moderate-to-high disease activity and are failing conventional synthetic DMARDs are put onto a TNFi as their first-line biologic.

It is estimated that roughly 2.8 million people are living with multiple sclerosis around the world. Because onset of the disease is most prevalent in the mid-30s, when people are often planning families and building careers, the disease can have a huge impact on their lives, families and society*. While corticosteroids have been proven effective in reducing inflammation in the brain for short term relief, they do not alter the long-term outcome of the disease, often leaving patients with symptom relapses and a progression of the disease.